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Abstract 
Background: Loratadine is a commonly used selective non‑sedating antihistaminic drug. Desloratadine is the active 
metabolite of loratadine and, in addition, a potential impurity in loratadine bulk powder stated by the United States 
Pharmacopeia as a related substance of loratadine. Published methods for the determination of both analytes suffer 
from limited throughput due to the time‑consuming steps and tedious extraction procedures needed for the analysis 
of biological samples. Therefore, there is a strong demand to develop a simple rapid and sensitive analytical method 
that can detect and quantitate both analytes in pharmaceutical preparations and biological fluids without prior sam‑
ple extraction steps.
Results: A highly‑sensitive and time‑saving micellar liquid chromatographic method is developed for the simultane‑
ous determination of loratadine and desloratadine. The proposed method is the first analytical method for the deter‑
mination of this mixture using a monolithic column with a mobile phase composed of 0.15 M sodium dodecyl sulfate, 
10% n‑Butanol and 0.3% triethylamine in 0.02 M phosphoric acid, adjusted to pH 3.5 and pumped at a flow rate of 
1.2 mL/min. The eluted analytes are monitored with fluorescence detection at 440 nm after excitation at 280 nm. 
The developed method is linear over the concentration range of 20.0–200.0 ng/mL for both analytes. The method 
detection limits are 15.0 and 13.0 ng/mL and the limits of quantification are 20.0 and 18.0 ng/mL for loratadine and 
desloratadine, respectively. Validation of the developed method reveals an accuracy of higher than 97% and intra‑ and 
inter‑day precisions with relative standard deviations not exceeding 2%.
Conclusions: The method can be successfully applied to the determination of both analytes in various matrices 
including pharmaceutical preparations, human urine, plasma and breast milk samples with a run‑time of less than 
5 min and without prior extraction procedures. The method is ideally suited for use in quality control laboratories. 
Moreover, it could be a simple time‑saving alternative to the official pharmacopeial method for testing desloratadine 
as a potential impurity in loratadine bulk powder.
Keywords: Loratadine, Desloratadine, Micellar monolithic HPLC, Fluorometric detection, Tablets, Biological fluids
© The Author(s) 2016. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
*Correspondence:  mohamedelawady2@yahoo.com 
1 Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, 
Mansoura University, Mansoura 35516, Egypt
Full list of author information is available at the end of the article
Page 2 of 11Belal et al. Chemistry Central Journal  (2016) 10:79 
Background
Allergies are one of the four most common issues for 
public health along with tumors, cardiovascular dis-
eases and AIDS. Each decade, a dramatic rise in allergies 
is observed in most countries. Histamine H1-receptor 
antagonists are the foremost known therapeutic agents 
used in the control of allergic disorders [1].
Loratadine (LOR) (Fig.  1) is a commonly used selec-
tive non-sedating H1-receptor antagonist which is not 
associated with performance impairment [2]. Deslorata-
dine (DSL) (Fig.  1), the descarboethoxy form and the 
major active metabolite of LOR, is also a non-sedating 
H1-receptor antagonist with an antihistaminic activity 
of 2.5–4 times as great as LOR [3]. Moreover, DSL is a 
potential impurity in LOR bulk powder stated by the 
United States Pharmacopeia [4] as a related substance 
of LOR. Chemically, both LOR and DSL are weak bases. 
The pKa of LOR is 5.25 at 25 °C while DSL has two pKa’s, 
4.41 and 9.97 at 25  °C [5]. The octanol/water partition 
coefficient log P of LOR is 5 [6] while of DSL is 3.2 [7]. 
The high similarities between LOR and DSL regarding 
structure and physicochemical properties renders their 
simultaneous analysis challenging. Different analytical 
methods have been published for the simultaneous deter-
mination of LOR and DSL including UPLC [8], HPLC [9–
24], HPTLC [25], TLC [26], GC [27] spectrophotometric 
[28] and capillary electrophoretic [29] methods. The 
main drawback of these methods is the limited through-
put due to required time-consuming steps. Considering 
biological applications, the reported methods for the 
analysis of LOR and DSL in biological fluids involve tedi-
ous and time-consuming preparative steps such as pro-
tein precipitation, liquid–liquid or solid-phase extraction 
and evaporation prior to the chromatographic separa-
tion. Therefore, there is still a strong demand to develop 
a simple rapid and sensitive analytical method that can 
detect and quantitate both analytes in pharmaceutical 
preparations and biological fluids without the need for 
sample pretreatment procedures.
The use of chromatographic methods for pharmaceuti-
cal analysis in comparison to other analytical methods has 
several advantages including high versatility, selectivity and 
efficiency, in addition to its ability to be coupled with differ-
ent sample extraction techniques [30–33]. Micellar liquid 
chromatography (MLC) is advantageous over conventional 
liquid chromatography due to several reasons including 
the smaller concentration of organic solvent in the mobile 
phase which render it cheaper and less toxic, the improved 
selectivity and ability to separate different hydrophobic and 
hydrophilic analytes due to variable mechanisms of inter-
action between analytes and the mobile and stationary 
phases, the excellent solubilizing power of micelles and the 
ability to use direct injection of complex sample matrices 
including biological fluids without pretreatment proce-
dures [34–36]. Monolithic silica is one of the new types of 
sorbents used in liquid chromatography. It is characterized 
by the ability to separate complicated sample mixtures with 
a very high efficiency and very short retention times using 
high flow rates with minimal back pressure due to the high 
porosity and permeability of the monolith as well as the 
presence of small-sized skeletons [37, 38].
The current study describes a novel, simple, sensitive 
and environment-friendly MLC–monolithic method 
for the simultaneous determination of LOR and DSL in 
Tablets and in spiked human plasma, urine and breast 
milk using fluorescence detection with a run-time of less 
than 5 min. To the best of our knowledge, the proposed 
method is the first MLC-monolithic method for the anal-
ysis of this mixture.
Experimental
Apparatus
Chromatographic measurements were performed with 
a Shimadzu LC-20AD Prominence liquid chromato-
graph (Japan) equipped with a Rheodyne injection valve 
(20-µL loop) and a RF-10AXL fluorescence detector. A 
Consort NV P-901 pH meter (Belgium) was used for pH 
measurements.
Materials and reagents
All the chemicals used were of Analytical Reagent grade, 
and the solvents were of HPLC grade. Loratadine (cer-
tified purity 99.7%) and desloratadine (certified purity 
99.6%) were kindly provided by Schering-Plough Co., 
USA. Sodium dodecyl sulfate (SDS) was obtained from 
Merck KGaA (Darmstadt, Germany). Triethylamine 
(TEA) and orthophosphoric acid, 85% were obtained 
from Riedel-de Haën (Seelze, Germany). Methanol, 
ethanol, n-propanol, n-Butanol and acetonitrile (HPLC 
grade) were obtained from Sigma-Aldrich (Germany).Fig. 1 Chemical structures of the studied analytes
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Pharmaceutical preparations containing the stud-
ied drugs were purchased from the local Egyptian mar-
ket. These include Loratadine 10  mg Tablets labeled to 
contain 10 mg of LOR (produced by Misr Company for 
Pharmaceutical Industries, Cairo, Egypt, batch#150103), 
Desa 5 mg Tablets labeled to contain 5 mg of DSL (pro-
duced by Delta Pharma Tenth of Ramadan City, Egypt, 
batch#31910).
The human plasma sample was kindly provided by 
Mansoura University Hospitals, Mansoura, Egypt and 
kept frozen at −5 °C until use after gentle thawing. Drug 
free urine sample was collected from a male healthy adult 
volunteer (30-years old). The breast milk sample was 
obtained from a female healthy volunteer (28-years old).
Chromatographic conditions
A Chromolith® Speed RODRP-18 (Merck, Germany) 
end-capped column (100  mm  ×  4.6  mm) was used in 
this study. The micellar mobile phase consisted of 0.15 M 
sodium dodecyl sulfate, 0.3% TEA and 10% n-Butanol 
in 0.02 M orthophosphoric acid, adjusted at pH 3.5. The 
mobile phase was filtered through 0.45-µm Millipore 
membrane filter and degassed by sonication for 30  min 
before use. The separation was performed at room tem-
perature with a flow rate of 1.2 mL/min and fluorescence 
detection at 440 nm after excitation at 280 nm.
Standard solutions
Stock solutions containing 200.0 μg/mL of each of LOR 
and DSL in methanol were prepared and used for maxi-
mum one week when stored in the refrigerator. Working 
standard solutions were prepared by appropriate dilution 
of the stock solutions with the mobile phase.
General procedure and construction of the calibration 
graphs
Accurately measured aliquots of the stock solutions 
were transferred into a series of 10-mL volumetric flasks 
and completed to volume with the mobile phase so that 
the final concentrations of the working standard solu-
tions were in the range of 20–200 ng/mL for both LOR 
and DSL. The standard solutions were then analyzed by 
injecting 20 μL aliquots (triplicate) and separation under 
the optimum chromatographic conditions. The aver-
age peak area versus the final concentration of the drug 
in ng/mL was plotted to get the calibration graphs and 
then linear regression analysis of the obtained data was 
performed.
Analysis of pharmaceutical preparations
An accurately weighed amount of the mixed contents 
of 20 finely powdered tablets equivalent to 10.0  mg of 
LOR or 5.0  mg of DSL was transferred into a 50.0-mL 
volumetric flask and about 20 mL of methanol was added. 
The flasks were then sonicated for 30 min, completed to 
the mark with methanol and filtered through a 0.45-μm 
membrane filter. Further dilution with the mobile phase 
was done to obtain the working standard solution to be 
analyzed as described under the section “General proce-
dure and construction of calibration graphs”. The recov-
ered concentration of each analyte was calculated from 
the corresponding regression equation.
Analysis of spiked biological fluids
New calibration graphs were constructed using spiked 
biological fluids as follows: 1 mL aliquots of human urine, 
plasma or breast milk samples were transferred into a 
series of 10-mL volumetric flasks, spiked with increas-
ing concentrations of LOR and DSL and then completed 
to the mark with the mobile phase and mixed well (final 
concentration was in the range of 5.0–50.0  ng/mL for 
both analytes). The solution were then filtered through 
a 0.45-μm membrane filter and directly injected into 
the chromatographic system under the above described 
chromatographic conditions. The linear regression equa-
tions relating the peak areas to the concentration (ng/
mL) were derived for each analyte.
Results and discussion
The proposed MLC method allows the simultaneous 
determination of LOR and DSL in pure form, tablets 
and biological fluids. Figure  2 illustrates a typical chro-
matogram for the analysis of a prepared mixture of LOR 
and DSL under the above described optimum chroma-
tographic conditions, where well-separated symmetrical 
Fig. 2 Typical chromatograms of a synthetic mixture of LOR and DSL 
(25 ng/mL of each) under the described chromatographic conditions: 
0.15 M sodium dodecyl sulphate, 0.3% TEA, 10% 1‑butanol in 0.02 M 
orthophosphoric acid, pH 3.5 and a flow rate of 1.2 mL/min
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peaks were observed. The migration order of analytes 
can be interpreted in terms of the electrostatic interac-
tion between analytes and the SDS monomers adsorbed 
on the stationary phase. In MLC, the main changes in 
the observed chromatographic performance are due to 
the adsorption of surfactant monomers on the station-
ary phase [36]. The modified stationary phase with SDS 
monomers is negatively charged and the studied analytes 
are positively charged at the mobile phase pH (3.5) which 
indicates a strong electrostatic attraction to the station-
ary phase. According to the pKa values of the analytes, 
DSL is doubly protonated at the mobile phase pH while 
LOR has a single positive charge. Therefore, the interac-
tion of DSL with the stationary phase is stronger and so 
its retention time is longer.
As starting chromatographic conditions, the following 
mobile phase was utilized: 0.15  M sodium dodecyl sul-
fate, 0.3% TEA and 10% n-propanol in 0.02 M orthophos-
phoric acid, adjusted to pH 6.0 with a flow rate of 1.0 mL/
min and using 290  nm as an excitation wavelength and 
438 nm as an emission wavelength. Optimization of the 
experimental parameters affecting the selectivity and effi-
ciency of the MLC system was performed by changing 
each in turn while keeping other parameters constant as 
shown in the following sections:
Method development
Choice of column
Two different columns were tested including: Chromo-
lith® Speed ROD RP-18 (Merck, Germany) end-capped 
column (100  mm  ×  4.6  mm) and Chromolith® Speed 
ROD RP-18 (Merck, Germany) end-capped column 
(50 mm × 4.6 mm). The first column showed better results 
where the peaks of both analytes were more symmetrical 
and well-defined with a total run time less than 5 min.
Choice of detection wavelength
The fluorescence behavior of both LOR and DSL was 
carefully studied in order to define the optimum wave-
length combination. The best sensitivity was achieved 
when 280 nm was used as the excitation wavelength and 
440 nm as the emission wavelength.
Effect of mobile phase composition
For optimum chromatographic separation, the effect of 
variation of the mobile phase composition was inten-
sively studied in order to achieve the highest selectivity 
and sensitivity of the developed method within a short 
analysis time. The study included the effect of variation 
of pH, variation of surfactant concentration and variation 
of type and concentration of the organic modifier. A sum-
mary of the results of this optimization study is presented 
in Table 1.
Variation of pH of the mobile phase The pH of the mobile 
phase was changed over the range of 2.5–6.0. As shown in 
Table 1, pH 3.5 was found to be the optimum pH showing 
well-resolved symmetrical peaks with the highest number 
of theoretical plates and highest resolution within a short 
run time.
Variation of  surfactant concentration The influence of 
different concentrations of SDS (0.05–0.175  M) on the 
selectivity, resolution and retention times of the studied 
analytes was investigated. By increasing the SDS con-
centration, the retention times of both analytes were 
decreased with better peak symmetry. As presented in 
Table 1, 0.15 M SDS was found to be the optimum giving 
the highest number of theoretical plates and the highest 
resolution.
Variation of type and concentration of the organic modi-
fier Different organic modifiers were investigated 
including acetonitrile, methanol, ethanol, n-propanol 
and n-Butanol. The best organic modifier was found to be 
n-Butanol showing satisfactory resolution and efficiency 
within a short run time (less than 5 min). The use of ace-
tonitrile, methanol, ethanol or n-propanol resulted in an 
increase in the retention time for both analytes with a 
decrease in the number of theoretical plates compared to 
the use of n-Butanol. That is because the addition of these 
solvents increases the polarity of the mobile phase relative 
to n-Butanol and since the studied analytes are hydropho-
bic compounds; this lead to an increase in the retention 
time for both analytes which is associated with larger peak 
width and lower number of theoretical plates.
The effect of variation of n-Butanol concentration on 
the chromatographic behavior of the studied analytes 
was investigated in the concentration range of 5.0–
12.0%. Based on the results obtained (see Table 1), 10.0% 
n-Butanol was found to be the optimum concentration 
regarding separation efficiency and resolution.
Effect of flow rate
Table  1 shows the effect of different flow rates (0.8–
1.5 mL/min) the chromatographic separation. A flow rate 
of 1.2 mL/min was chosen to be the optimum as it shows 
the highest efficiency in a short analysis time. Although 
lower flow rates showed higher resolution they were not 
selected as they lead to an increase in the total run time 
in addition to a decrease in the number of theoretical 
plates for both analytes.
Based on the above measurement series, the optimum 
chromatographic conditions were as follows:
The micellar mobile phase consists of 0.15  M sodium 
dodecyl sulfate, 0.3% TEA and 10% n-Butanol in 0.02 M 
orthophosphoric acid, adjusted at pH 3.5. A monolithic 
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C18 column was utilized. The separation was performed 
at room temperature with a flow rate of 1.2  mL/min 
and fluorescence detection at 440 nm after excitation at 
280 nm.
Validation of the method
Validation of the developed HPLC method was per-
formed according to the international conference on har-
monization (ICH) Guidelines [39]. Different validation 
characteristics were investigated as follows:
Linearity
The linearity of the developed method was confirmed by 
plotting the peak area against the analyte concentration 
in ng/mL. The graphs were linear over the concentra-
tion range of 20.0–200.0 ng/mL for both analytes. Linear 
regression analysis of the obtained data gave the follow-
ing regression equations:
P  =  −24.518  +  1.844C (r  =  0.9999) for LOR, 
P = −18.97 + 1.749C (r = 0.9999) for DSL.
Where P is the peak area, C is the analyte concentration 
in ng/mL and r is the correlation coefficient. Statistical 
analysis [40] of data showed high values of r, small values 
of the standard deviation of residuals (Sy/x), of intercept 
(Sa) and of slope (Sb), and small values of the percentage 
relative standard deviation which indicate linearity of the 
developed method over the studied concentration range 
(Table 2).
Accuracy
The accuracy of the proposed method was assessed by 
comparing the measured percent recovery of known 
added amounts of each drug into a blank matrix with 
those measured by the comparison method [41]. Statisti-
cal analysis of the results using Student’s t test and vari-
ance ratio F test [40] revealed no significant difference in 
Table 1 Optimization of  the chromatographic conditions for  separation of  the studied analytes by  the proposed HPLC 
method
Parameter No. of theoretical plates Resolution Tailing factor Selectivity factor (α)
LOR DSL LOR DSL
pH of the mobile phase
 2.5 1707 1738 3.25 1.34 1.23 1.75
 3.0 1811 1910 3.41 1.32 1.22 1.90
 3.5 2328 2693 4.93 1.31 1.21 1.94
 4.0 1601 2433 2.13 1.39 1.29 1.32
 5.0 1908 2508 2.94 1.44 1.3 1.63
 6.0 Unresolved peaks
SDS concentration (M)
 0.05 1584 1667 5.66 1.58 1.47 2.26
 0.1 1453 1627 4.91 1.52 1.44 1.94
 0.12 1501 2133 4.72 1.3 1.23 1.87
 0.15 2328 2693 4.93 1.31 1.21 1.94
 0.175 1918 2216 3.64 1.45 1.28 1.42
n‑Butanol concentration (%v/v)
 5% 692 727 4.52 2.03 1.77 1.76
 8% 1575 1825 4.12 1.29 1.28 1.71
 10% 2328 2963 4.93 1.31 1.21 1.94
 12% 1487 1938 3.83 1.45 1.33 1.59
Flow rate (mL/min)
 0.8 2190 2105 5.36 1.36 1.34 2.21
 1.0 1887 2328 5.12 1.39 1.29 2.16
 1.2 2328 2693 4.93 1.31 1.21 1.94
 1.5 1558 2117 3.93 1.20 1.14 1.62
Column temp.
 25 2328 2693 4.93 1.31 1.21 1.94
 35 1962 2206 4.02 1.98 2.11 1.77
 45 884 679 5.48 2.23 2.4 2.20
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the recoveries of the developed and comparison meth-
ods with regard to accuracy and precision, respectively 
(Tables 3, 4).
Precision
Intraday and interday precisions were evaluated for each 
analyte using three different concentrations and three 
replicates of each concentration. As shown in Table 3, the 
relative standard deviations were found to be very small 
which confirms the repeatability and intermediate preci-
sion of the developed method.
Selectivity
The method selectivity was tested by observing any inter-
ference encountered from common Tablet excipients. 
No interference was observed from any excipient, which 
indicates high selectivity of the proposed method. Addi-
tionally, no interference was encountered from blank 
human urine, plasma and breast milk matrices without 
any pretreatment steps.
Limit of quantification (LOQ) and method detection limit 
(MDL)
LOQ and MDL were determined according to ICH Q2 
(R1) recommendations [39]. MDL was determined by 
establishing the minimum level at which the analyte can 
reliably be detected (signal-to-noise ratio is 3:1) while 
LOQ was determined by establishing the lowest concen-
tration of analyte that can be determined with acceptable 
precision and accuracy (signal-to-noise ratio is 10:1). The 
MDL values were found to be 15.0 and 13.0 ng/mL and 
the LOQ values were 20.0 and 18.0 ng/mL for LOR and 
DSL, respectively (Table 2).
Robustness
The robustness of the method was evaluated by test-
ing its ability to remain unaffected by small but delib-
erate variations in the experimental parameters such 
as variation of: pH of the mobile phase (3.5  ±  0.1), 
n-Butanol concentration (10 ± 0.5%v/v) and SDS con-
centration (0.15 ± 0.01 M). These deliberate variations 
did not cause significant change of the peak area of 
Table 2 Analytical performance data for  the determina-
tion of the studied analytes by the proposed method
a Percentage relative standard deviation
b Method detection limit
c Limit of quantification
Parameter LOR DSL
Linearity range (ng/mL) 20.0–200.0 20.0–200.0
Intercept −24.518 −18.97
Slope 1.844 1.749
Correlation coefficient (r) 0.9999 0.9999
SD of residuals (Sy/x) 1.140 0.856
SD of intercept (Sa) 0.9054 0.679
SD of slope (Sb) 8.314 × 10−3 6.243 × 10−3
% RSDa 1.08 1.17
MDL (ng/mL)b 15.0 13.0
LOQ (ng/mL)c 20.0 18.0
Table 3 Precision data for the determination of the studied analytes by the proposed method
Each result is the average of three separate determinations
Parameter LOR DSL
20.0 ng/mL 100.0 ng/mL 200.0 ng/mL 20.0 ng/mL 100.0 ng/mL 200.0 ng/mL
Intraday precision
 % found 99.85 99.45 98.47 99.7 100.21 99.4
96.23 100.1 100.078 97.179 99.77 97.82
97.78 98.19 99.7 98.78 98.87 101.31
 Mean 97.95 99.25 99.42 98.55 99.62 99.51
 SD 1.82 0.97 0.84 1.28 0.68 1.75
 % RSD 1.85 0.98 0.85 1.30 0.69 1.76
 % error 1.07 0.57 0.49 0.75 0.40 1.01
Interday precision
 % found 97.25 100.43 99.46 100.58 99.47 98.63
100.48 97.6 97.84 101.01 97.58 97.01
99.95 99.85 98.724 99.85 100.94 100.78
 Mean 99.23 999.29 98.67 100.48 99.33 98.81
 SD 1.73 1.50 0.81 0.59 1.68 1.89
 % RSD 1.75 1.51 0.82 0.58 1.70 1.91
 % error 1.01 0.87 0.48 0.34 0.98 1.11
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The developed method was successfully applied to 
the assay of LOR and DSL in their Tablets (Fig. 3). The 
results obtained are summarized in Tables 4 and 5 show-
ing good agreement with those obtained by the compari-
son chromatographic method [41]. Statistical analysis 
of the results obtained using Student’s t test and vari-
ance ratio F test [39] indicated no significant difference 
between both them with regard to accuracy and preci-
sion, respectively.
Application to biological fluids
LOR undergoes rapid first-pass hepatic metabolism and 
its major metabolite is DSL. For LOR, the plasma Cmax 
is 30.5 ng/mL at 1.0 h after oral administration of 40-mg 
LOR capsule and for DSL, the plasma Cmax is 18.6 ng/mL 
at 2.2 h. About 40% is excreted as conjugated metabolites 
into the urine, and a similar amount is excreted into the 
feces. Traces of unmetabolized LOR can be found in the 
urine [42–44].
After a single oral dose of 40 mg of LOR, average peak 
milk level (20.4–39.0 ng/mL) occurred at 2.0 h after the 
dose while the average peak milk level of DSL is in the 
range of (9.0–29.6  ng/mL) occurred at 5.3  h after the 
dose [44].
Both drugs could be determined in spiked human 
urine, plasma and breast milk as shown in (Fig.  4). The 
results are summarized in Table 6. Under the previously 
described chromatographic conditions, new calibration 
graphs were established for each drug. The following lin-
ear regression equations relating the peak areas to the 
concentration (ng/mL) were derived:
P  =  5.662  +  0.535C (r  =  0.9999) for LOR in urine, 
P = 2.888 + 1.527C (r = 0.9998) for DSL in urine
P =  8.093 +  0.909C (r =  0.9998) for LOR in plasma, 
P = 4.496 + 1.353C (r = 0.9997) for DSL in plasma
P  =  8.364  +  0.889C (r  =  0.9998) for LOR in milk, 
P = 6.995 + 1.104C (r = 0.9998) for DSL in milk
where P is the peak area, C is the concentration of the 
drug in ng/mL and r is the correlation coefficient.
Conclusions
The current study represents a novel MLC method using 
a monolithic column for the simultaneous determination 
of LOR and DSL which is the major metabolite of LOR 
as well as one of its impurities. The developed method 
is able to separate both drugs with high resolution fac-
tor and high efficiency within a very short analysis time 
(less than 5 min). The method can be successfully applied 
for the assay of both analytes in their pharmaceutical 
Table 4 Assay results for the determination of the studied analytes in pure form by the proposed and official method [43]
a Each result is the average of three separate determinations
b The values between parentheses are the tabulated t and F values at P = 0.05
Analyte Proposed method Official method [43]
Amount taken (ng/mL) Amount found (ng/mL) % recoverya Amount taken (µg/mL) Amount found (µg/mL) % recoverya
LOR 20.0 20.400 102.01 5.0 4.900 98.01
50.0 50.300 100.61 30.0 30.030 100.1
80.0 79.700 99.63 50.0 49.990 99.98
100.0 99.200 99.21
200.0 200.400 100.21
Mean % 100.33 99.37
±SD 1.08 1.18
t testb 1.196 (2.447)
F testb 1.182 (6.944)
DSL 20.0 20.439 102.20 5.0 4.940 98.71
50.0 49.684 99.37 30.0 30.260 100.87
80.0 79.456 98.32 50.0 49.720 99.44
100.0 100.400 100.35
200.0 200.100 100.05
Mean % 100.26 99.67
±SD 1.17 1.10
t testb 0.697 (2.447)
F testb 1.137 (19.247)
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preparations and in spiked human urine, plasma and 
breast milk without prior extraction procedures. The val-
idation criteria of the developed MLC method indicate 
its reliability and allow its application in quality control 
analyses. Moreover, it can be utilized as a simple time-
saving alternative to the official pharmacopeial method 
for testing DSL as a potential impurity in LOR bulk 
powder.
Fig. 3 Chromatograms obtained from the application of the proposed method to the analysis of: a Loratadine 10 mg Tablets, b Desa 5 mg Tablets 
(analyte concentration: 25 ng/mL for both)
Table 5 Assay results for  the determination of  the studied analytes in  their different dosage forms by  the proposed 
and official method [41]
a Each result is the average of three separate determinations
b The values between parentheses are the tabulated t and F values at P = 0.05
Dosage form Proposed method Official method [41]
Amount taken  
(ng/mL)
Amount found  
(ng/mL)
% recoverya Amount taken  
(µg/mL)





50.0 51.636 103.27 5.0 4.950 98.99
100.0 97.556 97.56 30.0 30.150 100.5
200.0 200.800 100.41 50.0 49.610 99.22
Mean % 100.41 99.57
±SD 2.86 0.81
t testb 0.492 (2.776)
F testb 12.315 (19)
Desa 5 mg
Tablet
50.0 50.391 100.78 5.0 4.980 99.67
100.0 99.366 99.37 30.0 30.360 101.2
200.0 200.100 100.07 50.0 49.390 98.78
Mean % 100.07 99.88
±SD 0.71 1.22
t testb 0.233 (2.776)
F testb 3.014 (19)
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Fig. 4 Application of the proposed method to the determination of LOR and DSL in: spiked human urine: a Blank urine, b spiked urine (analyte 
concentration: 10 ng/mL), spiked human plasma. c Blank plasma, d spiked plasma (analyte concentration: 10 ng/mL for both), spiked breast milk.  
e Blank breast milk, f spiked breast milk (analyte concentration: 5 ng/mL for both)
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